Clinical trial
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic…
NCT00095264 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00095264 |
|---|---|
| Title | A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome |
| Official title | A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Darbepoetin Alfa |
| Enrollment | 209 |
| Start date | Oct 1, 2004 |
| First posted | Nov 3, 2004 |
| Last update posted | Jan 15, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: